DE69519634T2 - Pneumokokken-polysaccharid-rekombinante-pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen - Google Patents

Pneumokokken-polysaccharid-rekombinante-pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen

Info

Publication number
DE69519634T2
DE69519634T2 DE69519634T DE69519634T DE69519634T2 DE 69519634 T2 DE69519634 T2 DE 69519634T2 DE 69519634 T DE69519634 T DE 69519634T DE 69519634 T DE69519634 T DE 69519634T DE 69519634 T2 DE69519634 T2 DE 69519634T2
Authority
DE
Germany
Prior art keywords
pneumolysin
pneumococcal
recombinant
polysaccharid
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69519634T
Other languages
English (en)
Other versions
DE69519634D1 (de
Inventor
Joseph S-C Kuo
Heesoo K Ree
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DE69519634D1 publication Critical patent/DE69519634D1/de
Publication of DE69519634T2 publication Critical patent/DE69519634T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69519634T 1994-08-24 1995-08-10 Pneumokokken-polysaccharid-rekombinante-pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen Expired - Fee Related DE69519634T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/295,305 US5565204A (en) 1994-08-24 1994-08-24 Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
PCT/US1995/010227 WO1996005859A1 (en) 1994-08-24 1995-08-10 Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections

Publications (2)

Publication Number Publication Date
DE69519634D1 DE69519634D1 (de) 2001-01-18
DE69519634T2 true DE69519634T2 (de) 2001-06-13

Family

ID=23137126

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69519634T Expired - Fee Related DE69519634T2 (de) 1994-08-24 1995-08-10 Pneumokokken-polysaccharid-rekombinante-pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen

Country Status (14)

Country Link
US (1) US5565204A (de)
EP (1) EP0778781B1 (de)
JP (1) JP3927233B2 (de)
KR (1) KR100385411B1 (de)
AT (1) ATE198051T1 (de)
AU (1) AU704450B2 (de)
CA (1) CA2198251C (de)
DE (1) DE69519634T2 (de)
DK (1) DK0778781T3 (de)
ES (1) ES2152421T3 (de)
GR (1) GR3035081T3 (de)
IL (1) IL115047A (de)
PT (1) PT778781E (de)
WO (1) WO1996005859A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165762A (en) 1996-08-16 2000-12-26 Smithkline Beecham Corporation DNA encoding adenine phosphoribosyltransferase from Streptococcus pneumoniae
EP0941335A2 (de) 1996-10-31 1999-09-15 Human Genome Sciences Polynukleotide und sequenzen aus streptococcus pneumoniae
CA2284606A1 (en) * 1997-03-26 1998-10-01 Brigham And Women's Hospital, Inc. Method for generating saccharide fragments
US6087328A (en) * 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
KR100619350B1 (ko) * 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
US5882898A (en) * 1997-08-29 1999-03-16 Smithkline Beecham Corporation Streptococcus pneumoniae polynucleotides which encode folyl-polyglutamate synthetase (FPGS) polypeptides
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US5861281A (en) * 1997-10-30 1999-01-19 Smithkline Beecham Corporation Lacc
US6165763A (en) 1997-10-30 2000-12-26 Smithkline Beecham Corporation Ornithine carbamoyltransferase
US6274719B1 (en) * 1998-04-24 2001-08-14 Smithkline Beecham Corporation Gcp
KR100586804B1 (ko) * 1998-07-14 2006-06-07 와이어쓰 홀딩스 코포레이션 모노포스포릴 지질 에이를 함유하는 보조제 및 백신 조성물
US6268177B1 (en) 1998-09-22 2001-07-31 Smithkline Beecham Corporation Isolated nucleic acid encoding nucleotide pyrophosphorylase
WO2000026359A1 (en) * 1998-11-04 2000-05-11 Smithkline Beecham Corporation ftsX
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
WO2001007465A1 (en) * 1999-07-22 2001-02-01 Smithkline Beecham Corporation Ga1R
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ES2359625T3 (es) * 2000-12-28 2011-05-25 Wyeth Llc Proteina protectora recombinante de.
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
CN100443116C (zh) * 2002-11-07 2008-12-17 新纳几美国公司 治疗或预防肺炎球菌感染的组合物及其用途
US8084235B2 (en) 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CN100423774C (zh) * 2003-08-06 2008-10-08 美国政府健康及人类服务部 制备多糖-蛋白轭合物疫苗的方法
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
BRPI0707154B8 (pt) 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
US9370557B2 (en) * 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
CN101553246B (zh) * 2006-08-07 2019-05-21 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
EP2056871B1 (de) * 2006-08-07 2017-11-15 President and Fellows of Harvard College Proteinmatriximpfstoffe sowie verfahren zur herstellung und verabreichung dieser impfstoffe
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2009023300A2 (en) 2007-04-13 2009-02-19 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
JP5666310B2 (ja) 2008-12-03 2015-02-12 株式会社カネカ ホルミル基含有多孔質担体、それを用いた吸着体、およびそれらの製造方法
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
ES2850973T3 (es) 2010-08-23 2021-09-01 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
KR101315599B1 (ko) 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2710393C2 (ru) * 2014-01-21 2019-12-26 Пфайзер Инк. Способ получения иммуногенного конъюгата капсульный полисахарид Streptococcus pneumoniae-белок-носитель
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CA2968398A1 (en) 2014-11-21 2016-05-26 The Board Of Regents Of The University Of Oklahoma Pneumolysin mutants and methods of use thereof
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
EP3337321A4 (de) 2015-08-19 2019-07-17 President and Fellows of Harvard College Lipidierte psa-zusammensetzungen und verfahren
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110234658B (zh) 2017-01-31 2024-03-12 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112019026192B1 (pt) 2017-06-10 2022-05-10 Inventprise, Llc Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines

Also Published As

Publication number Publication date
GR3035081T3 (en) 2001-03-30
ES2152421T3 (es) 2001-02-01
IL115047A0 (en) 1995-12-08
JPH10504717A (ja) 1998-05-12
PT778781E (pt) 2001-03-30
EP0778781B1 (de) 2000-12-13
EP0778781A1 (de) 1997-06-18
WO1996005859A1 (en) 1996-02-29
AU704450B2 (en) 1999-04-22
AU3363695A (en) 1996-03-14
CA2198251C (en) 2007-06-12
IL115047A (en) 2005-08-31
US5565204A (en) 1996-10-15
DE69519634D1 (de) 2001-01-18
DK0778781T3 (da) 2001-01-02
KR970705410A (ko) 1997-10-09
CA2198251A1 (en) 1996-02-29
ATE198051T1 (de) 2000-12-15
JP3927233B2 (ja) 2007-06-06
KR100385411B1 (ko) 2003-12-11

Similar Documents

Publication Publication Date Title
DE69519634D1 (de) Pneumokokken-polysaccharid-rekombinante-pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen
DK0754055T3 (da) Gruppe A-streptokok-polysaccharid-immunogen-præparater og metoder
NO913812D0 (no) Oligosakkaridkonjugatvaksiner.
MC2178A1 (fr) Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
EA200801344A1 (ru) Пневмококковая полисахаридная конъюгатная вакцина
NO975546D0 (no) Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav
DE60045721D1 (de) Streptococcus pneumoniae Proteine und Impfstoffe
Alexander et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®)
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
Jennings Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease
ES2126616T3 (es) Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
DE3851630D1 (de) Antikörper gegen streptococcus.
CO5241277A1 (es) Vacuna

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US

8339 Ceased/non-payment of the annual fee